Skip to main content

Alaunos Therapeutics to Participate in Upcoming Investor Conferences in April

Written by Customer Service on . Posted in Public Companies.

HOUSTON, March 29, 2023 (GLOBE NEWSWIRE) — Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), a leading T-cell receptor (TCR) cell therapy company advancing a clinical-stage pipeline of therapeutics for solid tumors, today announced that company management will be participating in the following upcoming investor conferences.

Cantor’s The Future of Oncology Virtual Symposium
Date: Tuesday, April 4, 2023
Format: Fireside Chat and 1×1 Meetings
Location: Virtual

22nd Annual Needham Virtual Healthcare Conference
Date: Monday, April 17, 2023
Format: Company Presentation and 1×1 Meetings
Location: Virtual

A live webcast of the Needham presentation will be accessible on the Company’s website in the Investors section under Events & Presentations at www.alaunos.com. A replay of the webcast will be available on the Alaunos website for approximately 90 days following the presentation.

About Alaunos Therapeutics
Alaunos Therapeutics is a leader in the science of T-cell receptor cell therapy working to revolutionize solid cancer treatment and outcomes. The clinical-stage company’s TCR T-cell therapy (TCR-T) is one of the most advanced TCR programs targeting driver mutations in solid tumors with an ongoing Phase 1/2 trial of its TCR-T product candidates across six solid cancers. Alaunos is powered by two proprietary platforms: its elegantly efficient non-viral Sleeping Beauty cell engineering platform; and its hunTR® discovery platform, which is expanding its industry-leading library of TCRs against high-frequency driver mutations. Alaunos is a part of an ongoing collaboration with the National Cancer Institute (NCI), part of the National Institutes of Health (NIH), working to advance the science of TCR therapy. For more information, visit www.alaunos.com.

Investor Relations Contact:
Alex Lobo
Stern Investor Relations
alex.lobo@sternir.com

Media Contact:
Heather Anderson
6 Degrees PR
handerson@6degreespr.com

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.